Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
233.81
-2.47 (-1.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
February 11, 2022
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter.
Via
Benzinga
Expert Ratings For Alnylam Pharmaceuticals
February 11, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Earnings Scheduled For February 10, 2022
February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.
Via
Benzinga
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
February 10, 2022
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam Pharmaceuticals: Q4 Earnings Insights
February 10, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q4 earnings results on Thursday, February 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
February 03, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
January 21, 2022
If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly,...
Via
Benzinga
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
January 21, 2022
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-...
Via
Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
January 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...
Via
Benzinga
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
January 20, 2022
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
January 16, 2022
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts...
Via
Talk Markets
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
January 16, 2022
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...
Via
Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
January 03, 2022
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica...
Via
Benzinga
What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
January 03, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...
Via
Benzinga
51 Biggest Movers From Yesterday
December 28, 2021
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 27, 2021
Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%...
Via
Benzinga
34 Stocks Moving In Monday's Mid-Day Session
December 27, 2021
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY...
Via
Benzinga
BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops
December 27, 2021
Patients who received the drug didn't improve in the six-minute walking test.
Via
Investor's Business Daily
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
December 23, 2021
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...
Via
Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
December 14, 2021
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...
Via
Benzinga
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
November 22, 2021
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
November 22, 2021
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.